- support
- info@evidentic.com
- +49 (0) 30 959 99 8831
Therapeutic Secukinumab antibody from the original Cosentyx® commercial drug.
Showing all 8 results
ProductBatch | Antigen | Molecular Class | Drug Brand | Product Concentration | CoA | Quantity per vial | Storage Temperature | Expiry Date | Price from | |
|---|---|---|---|---|---|---|---|---|---|---|
IL-17A |
Monoclonal Antibody |
Cosentyx® |
150 mg/mL |
yes |
6 mg |
-80°C |
11/2022 |
324,90 € |
||
IL-17A |
Monoclonal Antibody |
Cosentyx® |
150 mg/mL |
– |
6 mg |
-80°C |
12/2017 |
301,50 € |
||
IL-17A |
Monoclonal Antibody |
Cosentyx® |
150 mg/mL |
– |
6 mg |
-80°C |
02/2019 |
301,50 € |
||
IL-17A |
Monoclonal Antibody |
Cosentyx® |
150 mg/mL |
– |
6mg |
-80°C |
12/2022 |
301,50 € |
||
IL-17A |
Monoclonal Antibody |
Cosentyx® |
150 mg/mL |
– |
6 mg |
-80°C |
03/2018 |
301,50 € |
||
IL-17A |
Monoclonal Antibody |
Cosentyx® |
150 mg/mL |
– |
6 mg |
-80°C |
09/2019 |
301,50 € |
||
IL-17A |
Monoclonal Antibody |
Cosentyx® |
150 mg/mL |
– |
6 mg |
-80°C |
06/2018 |
301,50 € |
||
IL-17A |
Monoclonal Antibody |
Cosentyx® |
150 mg/mL |
– |
6 mg |
-80°C |
12/2018 |
301,50 € |
| Drug name | Cosentyx® |
| INN | Secukinumab |
| API type | Secukinumab is a recombinant fully human monoclonal antibody selective for interleukin-17A. Secukinumab is of the IgG1/κ-class produced in Chinese Hamster Ovary (CHO) cells |
| Pharmacotherapeutic group | Immunosuppressants, interleukin inhibitors |
| ATC code | L04AC10 |
| Target of antibody | IL 17A; Synonyms: CTLA8, IL-17, IL-17A, IL17, Ctla-8, Ctla8, Il17, ChIL-17, IL-17F, IL17A, CTLA-8 |
| General function | |
| Short description | |
| Pharmacodynamic properties (Mechanism of action; Source EMA document) | Secukinumab is a fully human IgG1/κ monoclonal antibody that selectively binds to and neutralises the proinflammatory cytokine interleukin-17A (IL-17A). Secukinumab works by targeting IL-17A and inhibiting its interaction with the IL-17 receptor, which is expressed on various cell types including keratinocytes. As a result, secukinumab inhibits the release of proinflammatory cytokines, chemokines and mediators of tissue damage and reduces IL-17A-mediated contributions to autoimmune and inflammatory diseases. Clinically relevant levels of secukinumab reach the skin and reduce local inflammatory markers. As a direct consequence treatment with secukinumab reduces erythema, induration and desquamation present in plaque psoriasis lesions. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. IL-17A plays a key role in the pathogenesis of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis and is up-regulated in lesional skin in contrast to non-lesional skin of plaque psoriasis patients and in synovial tissue of psoriatic arthritis patients. The frequency of IL-17-producing cells was also significantly higher in the subchondral bone marrow of facet joints from patients with ankylosing spondylitis. |
| Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | Serum levels of total IL-17A (free and secukinumab-bound IL-17A) are initially increased in patients receiving secukinumab. This is followed by a slow decrease due to reduced clearance of secukinumab-bound IL-17A, indicating that secukinumab selectively captures free IL-17A, which plays a key role in the pathogenesis of plaque psoriasis. In a study with secukinumab, infiltrating epidermal neutrophils and various neutrophil-associated markers that are increased in lesional skin of plaque psoriasis patients were significantly reduced after one to two weeks of treatment. Secukinumab has been shown to lower (within 1 to 2 weeks of treatment) levels of C-reactive protein, which is a marker of inflammation. |
| Original license holder | |
| Marketing authorisation numbers | EU/1/14/980/001 - 007 |
| Marketing authorisation holder | Novartis Europharm Limited Frimley Business Park Camberley GU16 7SR United Kingdom |
| Name of the manufacturer of the biological active substance | |
| Name and address of the manufacturer(s) responsible for batch release | Roche Pharma AG Emil-Barrell-Str. 1, D-79639 Grenzach-Wyhlen Germany |
| Max shelf life | 36 months |
| Storage conditions | 2°C – 8°C |
| List of excipients | Sucrose L-histidine L-histidine hydrochloride-monohydrate Polysorbate 80 |
Evidentic GmbH
Martin-Buber-Str. 10
14163 Berlin
